Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease

Overview

This page covers Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease.

See Also

• [Mechanisms](/mechanisms)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Experiment Overview

Title: Metal Ion-Synuclein-Mitochondria Axis Validation in Parkinson's Disease

Overview

This page covers Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson's Disease.

See Also

• [Mechanisms](/mechanisms)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Experiment Overview

Title: Metal Ion-Synuclein-Mitochondria Axis Validation in Parkinson's Disease

Hypothesis Tested: The Metal Ion-Synuclein-Mitochondria (MISM) Axis Hypothesis - that dysregulated iron and copper homeostasis in dopaminergic [neurons](/entities/neurons) creates a convergent pathological environment promoting alpha-synuclein aggregation AND mitochondrial dysfunction through oxidative stress.

Primary Objective: Validate the causal relationship between metal ion dyshomeostasis, alpha-synuclein aggregation, and mitochondrial dysfunction in PD patient-derived models.

Secondary Objectives:

Study Design

Phase 1: In vitro Validation (Year 1)

1.1 Metal-Alpha-Synuclein Aggregation Assays

Model System: Recombinant alpha-synuclein protein, iPSC-derived dopaminergic neurons

Experimental Groups:

• Control (no metal addition)
• Fe(III) treatment (various concentrations: 1, 5, 10, 25 μM)
• Cu(II) treatment (various concentrations: 0.1, 0.5, 1, 5 μM)
• Fe(III) + Cu(II) combination
• Iron chelator (deferoxamine) + metal
• Antioxidant (N-acetylcysteine) + metal

• ThT fluorescence kinetics (aggregation rate)
• TEM imaging (fibril morphology)
• SDS-PAGE/Western blot (oligomer species)
• Atomic force microscopy (fibril structure)

1.2 Mitochondrial Function Assays

Model System: iPSC-derived dopaminergic neurons from PD patients and healthy controls

Treatments:

• Iron overload (ferric ammonium citrate: 10, 50, 100 μM)
• Copper overload (copper sulfate: 1, 5, 10 μM)
• Iron chelation (deferoxamine: 50 μM)
• Combination treatments

• Seahorse XF analysis (OCR, ATP production)
• MitoSOX imaging (mitochondrial ROS)
• Mitochondrial membrane potential (TMRE)
• Complex I-V activities
• mtDNA copy number

1.3 Oxidative Stress Markers

Readouts:

• 8-OHdG (DNA oxidation) - immunostaining, ELISA
• 4-HNE (lipid peroxidation) - Western blot, mass spectrometry
• Protein carbonylation - OxyBlot assay
• GSH/GSSG ratio - HPLC
• Catalase, SOD activities - enzymatic assays

Phase 2: Animal Validation (Year 1-2)

2.1 Mouse Model Studies

Models:

• C57BL/6J wild-type + MPTP lesion
• A53T alpha-synuclein transgenic mice
• HFE knockout mice (iron overload model)
• Cross: A53T × HFE-/-

Endpoints (12 weeks):

• Behavioral: Rotarod, cylinder test, gait analysis
• Histology: TH+ neuron count, iron staining (Perls), alpha-synuclein aggregation (pSer129)
• Biochemistry: Mitochondrial function, oxidative stress markers
• MRI: Quantitative susceptibility mapping (QSM) for iron

2.2 Mechanistic Studies

Viral Vector Approaches:

• AAV-FTH1 (ferritin heavy chain) overexpression
• AAV-CP (ceruloplasmin) overexpression
• shRNA targeting DMT1 (divalent metal transporter)

Phase 3: Clinical Translation (Year 2-3)

3.1 Biomarker Discovery Cohort

Participants:

• Early-stage PD (n=100)
• Prodromal PD (n=50)
• Healthy controls (n=100)

• Serum: Ferritin, transferrin, ceruloplasmin, hepcidin
• CSF: Iron, copper, ferritin, alpha-synuclein, oxidative stress markers
• Imaging: QSM-MRI for brain iron, R2* for substantia nigra

• Biomarker levels vs. MDS-UPDRS scores
• Biomarker levels vs. disease duration
• Biomarker levels vs. genetic status ([GBA](/entities/gba), [LRRK2](/entities/lrrk2), SNCA)

3.2 Pilot Clinical Trial

Design: Randomized, double-blind, placebo-controlled

Intervention:

• Treatment: Deferasirox (30 mg/kg/day oral)
• Duration: 12 months
• Sample size: n=60 per arm

• Change in MDS-UPDRS Part III (motor) score

• CSF biomarkers (iron, alpha-synuclein, oxidative stress)
• QSM-MRI brain iron
• Timed Up and Go test
• Quality of Life (PDQ-39)

Statistical Analysis Plan

Sample Size Calculations

In vitro:

• Power: 0.80, α = 0.05
• Expected effect size: 30% reduction in aggregation with chelation
• n = 3 replicates × 6 conditions = 18 per experiment

• Power: 0.80, α = 0.05
• Expected effect: 25% improvement in behavioral scores
• n = 15 per group (6 groups = 90 total)

• Power: 0.80, α = 0.05
• Expected difference: 4 points on MDS-UPDRS
• n = 60 per arm (120 total)

Analysis Methods

• ANOVA with Tukey post-hoc for multiple comparisons
• Linear mixed models for longitudinal data
• Correlation analysis (Pearson/Spearman)
• Kaplan-Meier for progression analysis
• Machine learning for biomarker panel optimization

Risk Assessment

Potential Risks

Mitigation Strategies

Budget Estimate

| Phase | Item | Cost (USD) |
|-------|------|------------|
| Phase 1 | iPSC differentiation, reagents | $200,000 |
| Phase 1 | Animal studies | $300,000 |
| Phase 2 | Biomarker cohort | $150,000 |
| Phase 2 | Clinical trial (preclinical) | $500,000 |
| Phase 3 | Pilot clinical trial | $2,000,000 |
| Total | | $3,150,000 |

Timeline

| Milestone | Target Date |
|-----------|--------------|
| Phase 1 start | Month 1 |
| Phase 1 complete | Month 12 |
| Phase 2 start | Month 10 |
| Phase 2 complete | Month 36 |
| Biomarker cohort complete | Month 30 |
| Clinical trial start | Month 24 |
| Final analysis | Month 48 |

Expected Outcomes

Primary

Secondary

Related Pages

• [Metal Ion-Synuclein-Mitochondria Axis Hypothesis](/hypotheses/metal-ion-synuclein-mitochondria-axis-parkinsons)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Oxidative Stress](/mechanisms/oxidative-stress)

References